Amino-dihydrothiazine and amino-dioxido dihydrothiazine compounds as beta-secretase antagonists and methods of use
US9556135B2 · kind B2 · utility
Assignee
Inventors
- Richard T. Lewis
- Jennifer R. Allen
- Yuan Cheng
- Deborah Choquette
- Oleg Epstein
- Angel Guzman-Perez
- Paul E. Harrington
- Zihao Hua
- Randall W. Hungate
- Jason Brooks Human
- Ted Judd
- Qingyian Liu
- Patricia Lopez
- Ana Elena Minatti
- Philip R. Olivieri
- Karina Romero
- Shannon Rumfelt
- Robert M. Rzasa
- Laurie B. Schenkel
- John Stellwagen
- Ryan White
- Qiufen Xue
- Xiao Mei Zheng
- Wenge Zhong
Key dates
| Filing date | Oct 10, 2013 |
| Grant date | Jan 31, 2017 |
| Priority date | — |
| Expiry date | Oct 10, 2033 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D519/00
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A4, A5, A6, A8, R1, R2, R3, R7 and n of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and corresponding uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formula II and sub-formula embodiments thereof, intermediates and processes and methods useful for the preparation of compounds of Formulas I-II.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.